{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-103942","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.310884+00:00","generated_at":"2026-05-31T00:43:02.306162+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC","bullets":["Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).","Evaluates DKN-01 + bevacizumab + chemo as second-line therapy for advanced colorectal cancer.","Primary endpoint: progression-free survival overall and in left-sided CRC subpopulation.","Initial data from Part B expected in mid-2025; Part A showed encouraging response rates.","Study expanded from 130 to 188 patients, reflecting investigator and patient interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-103942","json":"https://secwatch.observer/filing/0001104659-24-103942.json","markdown":"https://secwatch.observer/filing/0001104659-24-103942.md","text":"https://secwatch.observer/filing/0001104659-24-103942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/0001104659-24-103942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/tm2425162d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:43:02.306162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}